Literature DB >> 16464173

Molecular genetics of human hypertension.

Maolian Gong1, Norbert Hubner.   

Abstract

EH (essential hypertension) is a major public health problem in many countries due to its high prevalence and its association with coronary heart disease, stroke, renal disease, peripheral vascular disease and other disorders. Epidemiological studies have demonstrated that EH is heritable. Owing to the fact that blood pressure is controlled by cardiac output and total peripheral resistance, many molecular pathways are believed to be involved in the disease. In this review, recent genetic studies investigating the molecular basis of EH, including different molecular pathways, will be highlighted.

Entities:  

Mesh:

Year:  2006        PMID: 16464173     DOI: 10.1042/CS20050208

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  16 in total

Review 1.  Potential dopamine-1 receptor stimulation in hypertension management.

Authors:  Mohammad Asghar; Seyed K Tayebati; Mustafa F Lokhandwala; Tahir Hussain
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

2.  Population differences in associations of serotonin transporter promoter polymorphism (5HTTLPR) di- and triallelic genotypes with blood pressure and hypertension prevalence.

Authors:  Redford B Williams; George D Bishop; Brett C Haberstick; Andrew Smolen; Beverly H Brummett; Ilene C Siegler; Michael A Babyak; Xiaodong Zhang; E Shyong Tai; Jeannette Jen-Mai Lee; Maudrene Tan; Yik Ying Teo; Shiwei Cai; Edmund Chan; Carolyn Tucker Halpern; Eric A Whitsel; Shawn Bauldry; Kathleen Mullan Harris
Journal:  Am Heart J       Date:  2016-12-29       Impact factor: 4.749

3.  DEspR T/CATAAAA-box promoter variant decreases DEspR transcription and is associated with increased BP in Sardinian males.

Authors:  Nicola Glorioso; Victoria L M Herrera; Tamara Didishvili; Giuseppe Argiolas; Chiara Troffa; Patrizia Bulla; Emanuela Bulla; Nelson Ruiz-Opazo
Journal:  Physiol Genomics       Date:  2011-08-23       Impact factor: 3.107

4.  ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects.

Authors:  Na Lu; Yang Yang; Yibo Wang; Yan Liu; Gang Fu; Dongmei Chen; Hui Dai; Xiaohan Fan; Rutai Hui; Yang Zheng
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

5.  Gene by stress genome-wide interaction analysis and path analysis identify EBF1 as a cardiovascular and metabolic risk gene.

Authors:  Abanish Singh; Michael A Babyak; Daniel K Nolan; Beverly H Brummett; Rong Jiang; Ilene C Siegler; William E Kraus; Svati H Shah; Redford B Williams; Elizabeth R Hauser
Journal:  Eur J Hum Genet       Date:  2014-10-01       Impact factor: 4.246

Review 6.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

7.  Specific Binding of Tetratricopeptide Repeat Proteins to Heat Shock Protein 70 (Hsp70) and Heat Shock Protein 90 (Hsp90) Is Regulated by Affinity and Phosphorylation.

Authors:  Victoria A Assimon; Daniel R Southworth; Jason E Gestwicki
Journal:  Biochemistry       Date:  2015-11-25       Impact factor: 3.162

Review 8.  Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review.

Authors:  Amy K Mottl; David A Shoham; Kari E North
Journal:  Genet Med       Date:  2008-08       Impact factor: 8.822

9.  Epistatic study reveals two genetic interactions in blood pressure regulation.

Authors:  Ndeye Coumba Ndiaye; El Shamieh Said; Maria G Stathopoulou; Gérard Siest; Michael Y Tsai; Sophie Visvikis-Siest
Journal:  BMC Med Genet       Date:  2013-01-08       Impact factor: 2.103

10.  Dahl (S x R) congenic strain analysis confirms and defines a chromosome 5 female-specific blood pressure quantitative trait locus to <7 Mbp.

Authors:  Victoria L M Herrera; Khristine A Pasion; Ann Marie Moran; Nelson Ruiz-Opazo
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.